Search PubMed⌕ Search

Biomedical subjects

R B Weiss

Publications and source records attributed to R B Weiss.

At least 217 records · Page 12Linked to original sources
PubMed1975

Hodgkin's disease in the bone marrow.

Tumor involvement of the bone marrow in patients with Hodgkin's disease may be suspected in the presence of other manifestations of advanced disease such as fever, lymphopenia, hypoalbuminemia, mixed cellular histologic type, or Stage III or IV disease by other clinical parameters. It occurs more frequently in the older age groups. When anemia, leucopenia, and/or thrombocytopenia are present and are unrelated to recent bone marrow suppressant chemotherapy, marrow involvement is likely to be present. Bone marrow examination, done by multiple trephine biopsies, provides an adequate sampling of tissue and results in a high incidence of detection of involvement by Hodgkin's disease. This manifestation of Hodgkin's disease is associated with a relatively short survival. Aggressive combination chemotherapy is necessary to produce a significant remission.

Adult↗
PubMedDate not supplied

Hemolytic anemia associated with antineoplastic agents.

Hemolytic anemia is an uncommon, but important, complication following the administration of antineoplastic agents. Three types of hemolytic anemia have been reported: microangiopathic hemolytic anemia, immune hemolytic anemia, and oxidative hemolysis. Physicians should be alert to the possibility of this adverse effect in any patient who has a sudden or unexplained drop in hemoglobin concentration while undergoing cancer chemotherapy. If the hemolytic anemia is not recognized and allowed to continue, the consequences may prove to be fatal.

Anemia, Hemolytic↗
PubMedDate not supplied

Hypersensitivity reactions induced by etoposide.

Eight patients with hypersensitivity to etoposide are reported. The clinical characteristics and outcome of the patients are detailed. In four patients, treatment was given to ameliorate the symptoms. Two of these patients were successfully re-treated with etoposide after premedication with diphenhydramine and hydrocortisone. Hypersensitivity is now recognized as a form of acute toxicity occasionally occurring with this agent. The mechanism is unknown but several possibilities are discussed.

Adolescent↗
PubMedDate not supplied

Phase I study of ICRF-187 using a daily for 3 days schedule.

ICRF-187, the enantiomer of ICRF-159 formulated for iv use, was administered to 23 patients in a phase I clinical trial. The dose ranged from 500 to 1500 mg/m2 every day for 3 days and was repeated every 28 days. The toxic effects included moderate to severe leukopenia and thrombocytopenia, which recovered by the 21st day of a treatment cycle. Myelosuppression was more severe in patients with prior nitrosourea treatment. Nonmyelosuppressive toxic effects included nausea and vomiting, transient elevations in liver function tests, alopecia, and increased urinary clearances of iron and zinc. The starting dose for phase II trials should be 1250 mg/m2 daily for 3 days repeated at 21-day intervals.

Adolescent↗